Wai Chun Bio-Technology Limited announced that on 29 September 2022, its indirect non-wholly-owned subsidiary, Century-Light, entered into a loan agreement with a borrower ultimately controlled by Mr. Liu Weijie. The agreement was designed to support the borrower's development of factory facilities and acquisition of production machinery. The borrower, as well as Weifang Shengtai Pharmaceutical Co., Ltd., are both controlled by Mr. Liu, a long-standing business partner of the Group. All drawdowns under the loan agreement, along with the relevant interest payments, were fully settled by the borrower to Century-Light in May 2025. This transaction was classified under major and disclosable transactions and involved compliance considerations with Hong Kong's Listing Rules.